title: Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.
abstract: This article reviews current pharmacologic treatment options for 3 common men's health concerns: hypogonadism, erectile dysfunction (ED), and benign prostatic hyperplasia (BPH). Specific topics addressed include: management of male hypogonadism using testosterone replacement therapy, use of oral phosphodiesterase inhibitors as first-line therapy for men with ED and the utility of intraurethral and intrapenile alprostadil injections for patients who do not respond to oral medications, and the role of alpha1-adrenergic antagonists, 5-alpha-reductase inhibitors, anticholinergic agents, and herbal therapies in the management of BPH.
authors.affiliation: Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Box 356426, Seattle, WA 98195, USA. Electronic address: keberks@uw.edu.
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Berkseth
authors.affiliation: Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, HSB C-209, UW Box# 357138, Seattle, WA 98195, USA.
authors.forename: Arthi
authors.initials: A
authors.lastname: Thirumalai
authors.affiliation: Department of Medicine, University of Washington, 4245 Roosevelt Way Northeast, Box #354760, Seattle, WA 98105, USA.
authors.forename: John K
authors.initials: JK
authors.lastname: Amory
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D054526:Men's Health; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D058891:5-alpha Reductase Inhibitors; D010726:Phosphodiesterase Inhibitors; D013739:Testosterone
keywords: Benign prostatic hyperplasia (BPH); Erectile dysfunction (ED); Male hypogonadism; Pharmacologic treatment